Leflunomide to Treat Uveitis

NCT00001863 | Completed Phase 2

• 2 other identifiers: 99005999-EI-0059
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

This study will investigate the safety and effectiveness of the drug Leflunomide to treat uveitis-an inflammation of the eye caused by an immune system abnormality. Leflunomide suppresses immune system activity and has been shown to control autoimmune diseases, such as arthritis (joint inflammation), in animals. It has also improved symptoms in patients with rheumatoid arthritis, and the Food and Drug Administration has approved it for treating patients with this disease. Eye and joint inflammation may have similar causes, and medicines for arthritis often help patients with eye inflammation. This study will examine whether Leflunomide can help patients with uveitis. Patients with uveitis who are not responding well to steroid treatment and patients who have side effects from other medicines used to treat uveitis (such as cyclosporine, cyclophosphamide, methotrexate or azathioprine) or have refused treatment because of possible side effects of these medicines may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood test and eye examination. The eye exam includes a check of vision and eye pressure, examination of the back of the eye (retina) with an ophthalmoscope and the front of the eye with a microscope. They will also undergo a procedure called fluorescein angiography to look at the blood vessels of the eye. A dye called sodium fluorescein is injected into the bloodstream through a vein. After the dye reaches the blood vessels of the eye, photographs are taken of the retina. Study participants will be divided into two groups. One group will take 100 milligrams of Leflunomide once a day for 3 days and then 20 milligrams once a day for 6 months. The other group will take a placebo-a pill that looks like the Leflunomide pill but does not contain the medicine. All patients in both groups will also take prednisone. Patients will have follow-up examinations at weeks 1, 4, 8, 12, 16, and 24 (6 months) of the study. Each follow-up visit will include a repeat of the screening exams and an evaluation of side effects or discomfort from the medicine. Those who do well and want to continue their assigned treatment after 6 months can continue that treatment for another 6 months and will have follow-up exams at months 9 and 12.

Conditions

Uveitis

Keywords

Immunosuppression; Inflammation; Eye; Vision; Medication; Uveitis; Leflunomide; Vitritis

Interventions

Leflunomide DRUG

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of current intermediate or posterior uveitis, or panuveitis.
• Current evidence of active intraocular inflammation based on the presence of vitreous haze, active retinal lesions, retinal vasculitis, or cystoid macular edema.
• years of age or older.
• Visual acuity of 73 letters or fewer (Snellen equivalent: 20/40 or worse) in at least one eye.
• The ability to understand and sign an informed consent form which must be obtained prior to randomization.
• The diagnosis of intermediate uveitis requires the presence of vitritis and either peripheral retinal vascular disease, cellular debris in the inferior vitreous (vitreous snowballs), exudate on the pars plana, or peripheral retinal infiltrates. The diagnosis of posterior uveitis requires the presence of infiltrative retinal lesions involving the posterior pole of the eye, usually with vitritis and often times with cystoid macular edema. The amount of cystoid macular edema will be graded by a standard protocol using Fluorescein Angiogram. The diagnosis of pan-uveitis requires the finding of active anterior segment inflammation, vitritis, and infiltrative retinal lesions.

You may not qualify if:

• Ocular or systemic disease requiring greater than 1 mg/kg/day of prednisone or greater than 80 mg qd if patients weigh more than 80 kg, or requiring other systemic immunosuppressants.
• Periocular injections of corticosteroids within the previous 4 weeks.
• Intolerance or contraindications to corticosteroids.
• Female who is pregnant or lactating.
• Patient refuses to use contraception during the study and 24 months after termination of active study therapy or undergo a cholestyramine washout regimen or an activated charcoal regimen under the care of a physician following termination of study therapy, if child-bearing or fathering potential exists.
• Patients with Behcet's disease.
• Use of Latanoprost within 2 weeks prior to enrollment, or current or likely need for Latanoprost during the course of the study.
• Hypersensitivity to fluorescein dye.
• Contraindications to use of steroids at dose and schedule.
• SGOT (AST) or SGPT(ALT) greater than or equal to 2 times the upper limit of normal.
• Allergic or hypersensitivity to leflunomide or any excipients.

Sponsors & Collaborators

• National Eye Institute (NEI): lead

Study Sites (1)

National Eye Institute (NEI)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Whitcup SM, Nussenblatt RB. Treatment of autoimmune uveitis. Ann N Y Acad Sci. 1993 Nov 30;696:307-18. doi: 10.1111/j.1749-6632.1993.tb17166.x.

  PMID: 8109836 BACKGROUND

• Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol. 1994 Jul 15;118(1):39-45. doi: 10.1016/s0002-9394(14)72840-5.

  PMID: 8023874 BACKGROUND

• Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983 Sep;96(3):275-82. doi: 10.1016/s0002-9394(14)77814-6.

  PMID: 6614105 BACKGROUND

MeSH Terms

Conditions

Uveitis; Inflammation; Uveitis, Intermediate

Interventions

Leflunomide

Condition Hierarchy (Ancestors)

Uveal Diseases; Eye Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Isoxazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 2
• Purpose: TREATMENT
• Sponsor Type: NIH

Study Record Dates

• First Submitted: November 3, 1999
• First Posted: November 4, 1999
• Study Start: March 1, 1999
• Study Completion: February 1, 2003
• Last Updated: March 4, 2008

Record last verified: 2003-02

Locations

US (1)